A global, randomized registration-enabling Phase 3 trial of avapritinib versus sunitinib in patients with PDGFRA- and KIT-driven second-line advanced GIST who do not have the KIT V654A or T670I mutations
Phase of Trial: Phase III
Latest Information Update: 28 Oct 2019
Price : $35 *
At a glance
- Drugs Avapritinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms COMPASS-2L
- Sponsors Blueprint Medicines
- 28 Oct 2019 According to a Blueprint Medicines media release, the company plans to prioritize completion of the VOYAGER trial and delay initiation of this (COMPASS-2L) trial in second-line GIST.
- 01 Aug 2019 According to a Blueprint Medicines media release, this trial is expected to be initaiated by the end of 2019.
- 27 Mar 2019 According to a Blueprint Medicines media release, this trial is one of the trials which will be funded by the net proceeds of the public offering announced today by the company.